Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296395 · ClinicalTrials.gov registry record · NA
Vascular Aging and Lp299v Study
A NA study of Vascular Aging, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05296395: Active NA study of Vascular Aging, sponsored by Medical College of Wisconsin.
NCT05296395 is a NA study of Vascular Aging that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05296395, a NA study of Vascular Aging, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Emerging data suggest the gut microbiota regulates multiple mechanisms related to vascular aging, but no intervention targeting the gut microbiota has been tested in older adults without cardiovascular risk factors or cardiovascular disease. Early human data suggest an increase in potentially pathological gut metabolites such as trimethylamine-N-oxide (TMAO) are associated with older age, increased vascular stiffness, increased oxidative stress, and reduced nitric oxide (NO) bioavailability as evidenced by impaired endothelium-dependent vasodilation. Based on this data, the investigators hypothesize that supplementation with Lp299v will reverse human vascular aging in healthy older adults free of known traditional cardiovascular risk factors.
Primary Outcome
This is a measurement of endothelial function in the brachial artery
Conditions Studied
Interventions
- OTHER Lactobacillus Plantarum 299v in fermented oat drink
- OTHER Heat-Killed Placebo control fermented drink
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2027-09-22 |
| Phase | NA |
What the registry record for NCT05296395 still lists
NCT05296395 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Vascular Aging appearing as the primary indexed condition, and to 2 interventions - of which Lactobacillus Plantarum 299v in fermented oat drink is the first listed.
NCT05296395 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05296395 about?
NCT05296395 is a clinical study titled "Vascular Aging and Lp299v Study". Emerging data suggest the gut microbiota regulates multiple mechanisms related to vascular aging, but no intervention targeting the gut microbiota has been tested in older adults without cardiovascular risk factors or cardiovascular disease. Early human data suggest an increase in potentially pathol...
What is the current status of trial NCT05296395?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-02-01. Estimated completion is 2027-09-22.
What conditions does trial NCT05296395 study?
This clinical trial studies the following conditions: Vascular Aging.
What interventions are being tested in trial NCT05296395?
The interventions under investigation include: Lactobacillus Plantarum 299v in fermented oat drink (OTHER), Heat-Killed Placebo control fermented drink (OTHER).
Who is sponsoring clinical trial NCT05296395?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296395 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05296395's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI